D C Klonoff

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Inhaled insulin
    D C Klonoff
    University of California at San Francisco, Burlingame, California, USA
    Diabetes Technol Ther 1:307-13. 1999
  2. ncbi A flaw in the use of sulfonylurea screening to diagnose sulfonylurea overdosages
    David C Klonoff
    Dorothy L. and James E. Frank Diabetes Research Institute, Mills-Peninsula Health Services, San Mateo, California 94401, USA
    Diabetes Technol Ther 5:453-4. 2003
  3. ncbi An economic analysis of interventions for diabetes
    D C Klonoff
    Department of Medicine, University of California at San Francisco, USA
    Diabetes Care 23:390-404. 2000
  4. ncbi A review of continuous glucose monitoring technology
    David C Klonoff
    University of California San Francisco, San Francisco, California, USA
    Diabetes Technol Ther 7:770-5. 2005
  5. ncbi Technological advances in the treatment of diabetes mellitus: better bioengineering begets benefits in glucose measurement, the artificial pancreas, and insulin delivery
    David C Klonoff
    Mills Peninsula Diabetes Research Institute, San Mateo, California 94401, USA
    Pediatr Endocrinol Rev 1:94-100. 2003
  6. ncbi Continuous glucose monitoring: roadmap for 21st century diabetes therapy
    David C Klonoff
    Mills-Peninsula Health Services Diabetes Research Institute, 100 S. San Mateo Dr, Rm. 3124, San Mateo, CA 94401, USA
    Diabetes Care 28:1231-9. 2005
  7. ncbi Current, emerging, and future trends in metabolic monitoring
    David C Klonoff
    Diabetes Technol Ther 4:583-8. 2002
  8. ncbi The First Annual Diabetes Technology Meeting--a new forum for accelerating the development of technology to fight diabetes
    David C Klonoff
    Diabetes Technol Ther 4:201-2. 2002
  9. ncbi Subcutaneous continuous glucose monitoring in severe burn patients
    David C Klonoff
    Crit Care Med 35:1445; author reply 1445-6. 2007
  10. ncbi Time synching or time sinking?
    Daniel J Crowe
    Diabetes Technol Ther 7:663-4. 2005

Collaborators

Detail Information

Publications18

  1. ncbi Inhaled insulin
    D C Klonoff
    University of California at San Francisco, Burlingame, California, USA
    Diabetes Technol Ther 1:307-13. 1999
    ..Inhaled insulin will become established if ongoing studies continue to demonstrate this technology to be safe and effective...
  2. ncbi A flaw in the use of sulfonylurea screening to diagnose sulfonylurea overdosages
    David C Klonoff
    Dorothy L. and James E. Frank Diabetes Research Institute, Mills-Peninsula Health Services, San Mateo, California 94401, USA
    Diabetes Technol Ther 5:453-4. 2003
  3. ncbi An economic analysis of interventions for diabetes
    D C Klonoff
    Department of Medicine, University of California at San Francisco, USA
    Diabetes Care 23:390-404. 2000
    ..Widely practiced interventions for patients with diabetes can be clearly cost-saving and clearly cost-effective. These practices are attractive from both a medical and an economic perspective...
  4. ncbi A review of continuous glucose monitoring technology
    David C Klonoff
    University of California San Francisco, San Francisco, California, USA
    Diabetes Technol Ther 7:770-5. 2005
  5. ncbi Technological advances in the treatment of diabetes mellitus: better bioengineering begets benefits in glucose measurement, the artificial pancreas, and insulin delivery
    David C Klonoff
    Mills Peninsula Diabetes Research Institute, San Mateo, California 94401, USA
    Pediatr Endocrinol Rev 1:94-100. 2003
    ..new routes of insulin administration, including inhaled, oral, buccal, nasal, and transdermal drug delivery systems. These new technologies will facilitate proper treatment of type 1 diabetes and improve the lives of affected patients...
  6. ncbi Continuous glucose monitoring: roadmap for 21st century diabetes therapy
    David C Klonoff
    Mills-Peninsula Health Services Diabetes Research Institute, 100 S. San Mateo Dr, Rm. 3124, San Mateo, CA 94401, USA
    Diabetes Care 28:1231-9. 2005
  7. ncbi Current, emerging, and future trends in metabolic monitoring
    David C Klonoff
    Diabetes Technol Ther 4:583-8. 2002
  8. ncbi The First Annual Diabetes Technology Meeting--a new forum for accelerating the development of technology to fight diabetes
    David C Klonoff
    Diabetes Technol Ther 4:201-2. 2002
  9. ncbi Subcutaneous continuous glucose monitoring in severe burn patients
    David C Klonoff
    Crit Care Med 35:1445; author reply 1445-6. 2007
  10. ncbi Time synching or time sinking?
    Daniel J Crowe
    Diabetes Technol Ther 7:663-4. 2005
  11. ncbi Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials
    John B Buse
    Division of Endocrinology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
    Clin Ther 29:139-53. 2007
    ..Some patients were followed up in open-label extensions to provide 'real-world' exenatide clinical experience...
  12. ncbi An adaptive drug infusion system
    Meghan Simmons
    TheraFuse, Inc, Carlsbad, California 92008, USA
    Diabetes Technol Ther 6:607-20. 2004
    ..CONCLUSIONS: The performance of the prototypes demonstrates that real-time compensation of flow variables provides significant performance improvements in therapeutic infusion...
  13. ncbi The need for separate performance goals for glucose sensors in the hypoglycemic, normoglycemic, and hyperglycemic ranges
    David C Klonoff
    Diabetes Care 27:834-6. 2004
  14. ncbi Microdialysis of interstitial fluid for continuous glucose measurement
    David C Klonoff
    Diabetes Technol Ther 5:539-43. 2003
  15. ncbi The link between diabetes, military metabolic monitoring, and NASA
    David C Klonoff
    Diabetes Technol Ther 5:351-3. 2003
  16. ncbi Diabetes and telemedicine: is the technology sound, effective, cost-effective, and practical?
    David C Klonoff
    Diabetes Care 26:1626-8. 2003
  17. ncbi European trends in diabetes technology--continuous glucose measurements and computerized information-processing tools
    David C Klonoff
    Diabetes Technol Ther 4:763-4. 2002
  18. ncbi Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
    David C Klonoff
    Diabetes Research Institute, Mills Peninsula Health Services, San Mateo, CA, USA
    Curr Med Res Opin 24:275-86. 2008
    ..The objective of this study was to evaluate the effects of > or = 3 years exenatide therapy on glycemic control, body weight, cardiometabolic markers, and safety...